At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 400 target
Drug / intervention
CENSUREother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Predicting Recurrence-Free Survival in Stage III and High-Risk Stage II Colorectal Cancer After Curative-Intent Treatment
In Brief
An observational study evaluating CENSURE for Colorectal Cancer and 4 related conditions. Currently recruiting, targeting 400 participants across 4 sites in 3 countries.
Detailed Summary
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Recurrent
CountriesChina, Spain, United States
Collaborators--
Timeline
N/ARecruitingOverdue
202420252026
Enrollment StartMar 2023
First PostedMar 2024
Primary CompletionJun 2026
TodayJul 2026
First PostedMar 18, 2024
Enrollment StartMar 15, 2023
Primary CompletionJun 18, 2026
TodayJul 1, 2026
Enrollment to primary: 3.3 yearsPosted 2.3 years ago
Interventions
CENSUREother
A panel of CpG sites, whose methylation level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.